{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:09:51Z","timestamp":1773281391990,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Inhaled epoprostenol (iEPO) has been shown to reduce pulmonary artery pressure and improve oxygenation. iEPO is mainly delivered via a syringe pump with feed tubing connected to a vibrating mesh nebulizer with high or low formulation concentration delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An in vitro study and a two-period retrospective case\u2013control study were implemented. The in vitro study compared iEPO delivery via invasive ventilation at low concentrations of 7.5, and 15\u00a0mcg\/mL and high concentration at 30\u00a0mcg\/mL, to deliver the ordered dose of 30 and 50\u00a0ng\/kg\/min for three clinical scenarios with predicted body weight of 50, 70 and 90\u00a0kg. While in the clinical study, adult patients receiving iEPO via invasive ventilation to treat refractory hypoxemia, pulmonary hypertension, or right ventricular failure were included. 80 patients received low concentration iEPO at multiple concentrations (2.5, 7.5, and 15\u00a0mcg\/mL, depending on the ordered dose) from 2015 to 2017, while 84 patients received high concentration iEPO at 30\u00a0mcg\/mL from 2018 to 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the in vitro study, there were no significant differences in aerosol deposition between high vs low concentrations of iEPO at a dose of 50\u00a0ng\/kg\/min. In the clinical study, age, gender, ethnicity, and indications for iEPO were similar between high and low concentration groups. After 30\u2013120\u00a0min of iEPO administration, both delivery strategies significantly improved oxygenation in hypoxemic patients and reduced mean pulmonary arterial pressure (mPAP) for patients with pulmonary hypertension. However, no significant differences of the incremental changes were found between two delivery groups. Compared to low concentration, high concentration delivery group had better adherence to the iEPO weaning protocol (96% vs 71%, p\u2009&lt;\u20090.001), fewer iEPO syringes utilized per patient (5 [3, 10] vs 12 [6, 22], p\u2009=\u20090.001), and shorter duration of invasive ventilation (6 [3, 12] vs 9 [5, 18] days, p\u2009=\u20090.028). Intensive care unit length of stay and mortality were similar between two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to low concentration delivery of iEPO, high concentration iEPO via a vibrating mesh nebulizer maintained clinical benefits and increased clinician compliance with an iEPO weaning protocol, required less medication preparation time, and shortened duration of invasive ventilation.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12931-021-01827-4","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T08:02:37Z","timestamp":1629532957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-1291","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley E.","family":"Augustynovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal K.","family":"Gurnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"1827_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1213\/ANE.0000000000002138","volume":"125","author":"M Elmi-Sarabi","year":"2017","unstructured":"Elmi-Sarabi M, Deschamps A, Delisle S, et al. Aerosolized vasodilators for the treatment of pulmonary hypertension in cardiac surgical patients: a systematic review and meta-analysis. Anesth Analg. 2017;125:393\u2013402.","journal-title":"Anesth Analg"},{"issue":"6","key":"1827_CR2","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4187\/respcare.03927","volume":"60","author":"NS Hill","year":"2015","unstructured":"Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care. 2015;60(6):794\u2013802.","journal-title":"Respir Care"},{"issue":"10","key":"1827_CR3","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/1060028018776432","volume":"52","author":"JM Hawn","year":"2018","unstructured":"Hawn JM, Wanek M, Bauer SR, et al. Effectiveness, safety, and economic comparison of two inhaled epoprostentol products (flolan and veletri) in cardiothoracic surgery patients. Ann Pharmacother. 2018;52(10):956\u201364.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1827_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1177\/1060028018782209","volume":"52","author":"MA Ammar","year":"2018","unstructured":"Ammar MA, Sasidhar M, Lam SW. Inhaled epoprostenol through noninvasive routes of ventilator support systems. Ann Pharmacother. 2018;52(12):1173\u201381.","journal-title":"Ann Pharmacother"},{"key":"1827_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/pharmaceutics11060281","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, Harnois LJ, Markos B, et al. Epoprostenol delivered via high flow nasal cannula for ICU subjects with severe hypoxemia comorbid with pulmonary hypertension or right heart dysfunction. Pharmaceutics. 2019;11:281.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1827_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/jcm9020464","volume":"9","author":"J Li","year":"2020","unstructured":"Li J, Gurnani PK, Roberts KM, et al. The clinical impact of flow titration on epoprostenol delivery via high flow nasal cannula for ICU patients with pulmonary hypertension or right ventricular dysfunction: a retrospective cohort comparison study. J Clin Med. 2020;9(2):464.","journal-title":"J Clin Med"},{"issue":"12","key":"1827_CR7","doi-asserted-by":"publisher","first-page":"e0307","DOI":"10.1097\/CCE.0000000000000307","volume":"2","author":"J Li","year":"2020","unstructured":"Li J, Fink JB, Augustynovich AE, et al. Effects of inhaled epoprostenol and prone positioning in intubated coronavirus disease 2019 patients with refractory hypoxemia. Crit Care Explor. 2020;2(12):e0307.","journal-title":"Crit Care Explor"},{"key":"1827_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1378\/chest.14-3161","volume":"147","author":"BM Fuller","year":"2015","unstructured":"Fuller BM, Mohr NM, Skrupky L, et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest. 2015;147:1510\u201322.","journal-title":"Chest"},{"issue":"7","key":"1827_CR9","first-page":"CD007733","volume":"7","author":"A Afshari","year":"2017","unstructured":"Afshari A, Bastholm Bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2017;7(7):CD007733.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1827_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/0885066620906800","volume":"36","author":"MS Buckley","year":"2021","unstructured":"Buckley MS, Agarwal SK, Garcia-Orr R, et al. Comparison of fixed-dose inhaled epoprostenol and inhaled nitric oxide for acute respiratory distress syndrome in critically ill adults. J Intensive Care Med. 2021;36(4):466\u201376.","journal-title":"J Intensive Care Med"},{"issue":"18","key":"1827_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/ajhp\/zxz151","volume":"76","author":"SL Davis","year":"2019","unstructured":"Davis SL, Crow JR, Fan JR, et al. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: a quality improvement project. Am J Health Syst Pharm. 2019;76(18):1413\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"1827_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1060028019888853","volume":"54","author":"JM Hawn","year":"2020","unstructured":"Hawn JM, Bauer SR, Wanek MR, et al. Effectiveness, safety, and economic comparison of inhaled epoprostenol brands, flolan and veletri, in acute respiratory distress syndrome. Ann Pharmacother. 2020;54(5):434\u201341.","journal-title":"Ann Pharmacother"},{"key":"1827_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.4187\/respcare.05344","volume":"62","author":"AC Anderson","year":"2017","unstructured":"Anderson AC, Dubosky MN, Fiorino KA, et al. The effect of nebulizer position on aerosolized epoprostenol delivery in an adult lung model. Respir Care. 2017;62:1387\u201395.","journal-title":"Respir Care"},{"issue":"3","key":"1827_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0885066620976525","volume":"36","author":"R Sonti","year":"2021","unstructured":"Sonti R, Pike CW, Cobb N. Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19. J Intensive Care Med. 2021;36(3):327\u201333.","journal-title":"J Intensive Care Med"},{"key":"1827_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13054-020-03206-9","volume":"24","author":"J Li","year":"2020","unstructured":"Li J, Fink JB, MacLoughlin R, et al. A narrative review on trans-nasal pulmonary aerosol delivery. Crit Care. 2020;24:506.","journal-title":"Crit Care"},{"issue":"2","key":"1827_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ppul.24589","volume":"55","author":"J Li","year":"2020","unstructured":"Li J, Wu W, Fink JB. In Vitro comparison of unit dose versus infusion pump administration of albuterol via high-flow nasal cannula in toddlers. Pediatr Pulmonol. 2020;55(2):322\u20139.","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"1827_CR17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.4187\/respcare.01785","volume":"58","author":"A Tonnelier","year":"2013","unstructured":"Tonnelier A, Lellouche F, Bouchard PA, et al. Impact of humidification and nebulization during expiratory limb protection: an experimental bench study. Respir Care. 2013;58(8):1315\u201322.","journal-title":"Respir Care"},{"issue":"3","key":"1827_CR18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1213\/00000539-199909000-00021","volume":"89","author":"JS Walton","year":"1999","unstructured":"Walton JS, Fears R, Burt N, et al. Intraoperative breathing circuit obstruction caused by albuterol nebulization. Anesth Analg. 1999;89(3):650\u20131.","journal-title":"Anesth Analg"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-021-01827-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-021-01827-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T20:08:11Z","timestamp":1673122091000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-021-01827-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1827"],"URL":"https:\/\/doi.org\/10.1186\/s12931-021-01827-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Review Board at Rush University Medical Center, Chicago, IL (Approval No. 19073005-IRB01). Written consents were not required since this was a retrospective, observational cohort study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Li declares to receive research funding from Fisher & Paykel Healthcare Ltd, Aerogen Ltd, and Rice Foundation and lecture honorarium from AARC and Fisher & Paykel Healthcare Ltd outside the submitted work. Dr. Fink is Chief Science Officer for Aerogen Pharma Corp. The companies had no role in the study design, data collection, analysis, preparation of the manuscript, or the decision to publish the findings. Other authors have no conflicts to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}